Cargando…
STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial.
BACKGROUND: The Janus kinase (JAK) and signal transduction and activation of transcription (STAT) signaling pathway is an attractive target in multiple cancers. Activation of the JAK-STAT pathway is important in both tumorigenesis and activation of immune responses. In diffuse large B-cell lymphoma...
Autores principales: | Reilley, Matthew J., McCoon, Patricia, Cook, Carl, Lyne, Paul, Kurzrock, Razelle, Kim, Youngsoo, Woessner, Richard, Younes, Anas, Nemunaitis, John, Fowler, Nathan, Curran, Michael, Liu, Qinying, Zhou, Tianyuan, Schmidt, Joanna, Jo, Minji, Lee, Samantha J., Yamashita, Mason, Hughes, Steven G., Fayad, Luis, Piha-Paul, Sarina, Nadella, Murali V. P., Xiao, Xiaokun, Hsu, Jeff, Revenko, Alexey, Monia, Brett P., MacLeod, A. Robert, Hong, David S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6240242/ https://www.ncbi.nlm.nih.gov/pubmed/30446007 http://dx.doi.org/10.1186/s40425-018-0436-5 |
Ejemplares similares
-
Phase I Study of Acalabrutinib Plus Danvatirsen (AZD9150) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Including Circulating Tumor DNA Biomarker Assessment
por: Roschewski, Mark, et al.
Publicado: (2023) -
Advanced gynecologic malignancies treated with a combination of the VEGF inhibitor bevacizumab and the mTOR inhibitor temsirolimus
por: Piha-Paul, Sarina A., et al.
Publicado: (2014) -
P53 Mutations in Advanced Cancers: Clinical Characteristics, Outcomes, and Correlation between Progression-Free Survival and Bevacizumab-Containing Therapy
por: Said, Rabih, et al.
Publicado: (2013) -
Revisiting Clinical Trials Using EGFR Inhibitor-Based Regimens in Patients with Advanced Non-Small Cell Lung Cancer: A Retrospective Analysis of an MD Anderson Cancer Center Phase I Population
por: Wheler, Jennifer, et al.
Publicado: (2013) -
Dual EGFR inhibition in combination with anti-VEGF treatment in colorectal cancer
por: Falchook, Gerald S., et al.
Publicado: (2014)